Skip to main content

Drug Interactions between AmBisome and foscarnet

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

foscarnet amphotericin B liposomal

Applies to: foscarnet and AmBisome (amphotericin b liposomal)

GENERALLY AVOID: The potential nephrotoxicity of foscarnet and amphotericin B may be additive. Concomitant use of these drugs could also lead to additive hypokalemia, hypomagnesemia, and hypocalcemia, which may increase the foscarnet-related risks of QT prolongation and seizures.

MANAGEMENT: The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks. Electrolyte levels and renal function of patients receiving these medications concomitantly should be monitored carefully, and dosages adjusted or discontinued if necessary.

References

  1. Ringden O, Lonnqvist B, Paulin T, et al. (1986) "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother, 17, p. 373-87
  2. Deray G, Le Hoang P, Soubrie C, et al. (1987) "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet, 2, p. 216
  3. Cacoub P, Deray G, Baumelou A, et al. (1988) "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol, 29, p. 315-8
  4. Deray G, Martinez F, Katlama C, et al. (1989) "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol, 9, p. 316-21
  5. Willocks L, Brettle R (1992) "Foscarnet and pancytopenia." J Antimicrob Chemother, 29, p. 232
  6. Farese RV Jr, Schambelan M, Hollander H, et al. (1990) "Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis." Ann Intern Med, 112, p. 955-6
  7. Deray G, Katlama C, Dohin E (1990) "Prevention of foscarnet nephrotoxicity." Ann Intern Med, 113, p. 332
  8. Palestine AG, Polis MA, De Smet MD, et al. (1991) "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med, 115, p. 665-73
  9. Jacobson MA (1992) "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr, 5, s11-7
  10. SOCA Reseach Group, et al. (1992) "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med, 326, p. 213-20
  11. Blanshard C (1992) "Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet." J Acquir Immune Defic Syndr, 5, s25-8
  12. (2001) "Product Information. Foscavir (foscarnet)." Astra-Zeneca Pharmaceuticals
  13. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  14. Cerner Multum, Inc. "Australian Product Information."
  15. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  16. Cerner Multum, Inc. (2015) "Canadian Product Information."
  17. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
View all 17 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer